Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine in patients with Diffuse Large B-Cell Lymphoma.

The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab S/C in combination with cyclophosphamide, doxorubicin, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's Lymphoma.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL).

Citation

Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6674/672_v3_DA_SC_REPOCH.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-07-27	Health Service Executive	Indication approved for reimbursement.